AYTU - Aytu BioScience Inc

Momentum: Bearish

Recent News

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Aytu BioPharma ( NASDAQ:AYTU ) , Circle Internet Group ( NYSE:CRCL )

Benzinga • 2 months, 2 weeks ago • score: 0.33

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Aytu BioPharma, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and marketing novel products in the field of hypogonadism (low testosterone levels), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company is headquartered in Englewood, Colorado.

52W High

$2.85

52W Low

$0.95

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.23

Valuation

Attractive

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

3.69

EV/EBITDA (<8 favorable)

2.21

EV/Revenue (<3 favorable)

0.29

P/S (TTM) (<3 favorable)

0.25

P/B (<3 favorable)

0.58

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.58%

Institutions (25–75% balanced)

38.09%

Shares Outstanding

8,976,900

Float

3,913,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

81,659,000

Gross Profit (TTM)

52,891,000

EPS (TTM)

-1.49

Profit Margin (>10% good)

0.02%

Operating Margin (TTM) (higher better)

0.13%

ROE (TTM) (>15% strong)

-0.03%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.32

Momentum

Bearish momentum

Value

0.0038

-0.0037

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 12, 2025